Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): Data from a randomized-withdrawal, placebo-controlled maintenance study

Journal of Affective Disorders

Volumn 151, Issue 3, 2013, Pages 906-913

  Sheehan, David V ^a   Svedsäter, Henrik ^b   Locklear, Julie C ^c   Eriksson, Hans ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ASTRAZENECA R AND D   (Sweden)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Functioning; Generalized anxiety disorder; Patient reported outcomes; Quetiapine XR; Sleep quality

Indexed keywords

PLACEBO; QUETIAPINE;

ABSENTEEISM; ADULT; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; FAMILY LIFE; FEMALE; FUNCTIONAL ASSESSMENT; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; LETHARGY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHOOL; SCORING SYSTEM; SHEEHAN DISABILITY SCALE; SLEEP QUALITY; SOCIAL LIFE; SOMNOLENCE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME; WORK;

FUNCTIONING; GENERALIZED ANXIETY DISORDER; PATIENT-REPORTED OUTCOMES; QUETIAPINE XR; SLEEP QUALITY;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; HUMANS; MIDDLE AGED; SLEEP; YOUNG ADULT;

EID: 84886722556     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2013.07.037     Document Type: Article

References (45)

1. C. Allgulander, T. Jorgensen, A. Wade, C. Francois, N. Despiegel, P. Auquier, and M. Toumi Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial Curr. Med. Res. Opin. 23 2007 2543 2549
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fourth Edition 1994 American Psychiatric Association Washington, DC
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition, Text Revision 2000 American Psychiatric Association Washington, DC
4. AstraZeneca. Seroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information. December, 2012a. Available at: http://www1.astrazeneca-us.com/pi/seroquelxr.pdf (accessed July 9, 2012a).
5. AstraZeneca. Seroquel XR - Summary of Product Characteristics for Ireland. May 10, 2012b. Available at: http://www.medicines.ie/medicine/13032/ SPC/Seroquel+XR+50mg%2c+150mg%2c+200mg%2c+300mg%2c+400mg+prolonged- release+tablets/ (accessed May 18, 2012b).
6. D.S. Baldwin, I.M. Anderson, D.J. Nutt, B. Bandelow, A. Bond, J.R. Davidson, J.A. den Boer, N.A. Fineberg, M. Knapp, J. Scott, and H.U. Wittchen Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology 19 2005 567 596
7. D.S. Baldwin, and N. Tiwari The pharmacologic treatment of patients with generalized anxiety disorder: where are we now and where are we going? CNS Spectrums 14 2009 5 12
8. B. Bandelow, G. Chouinard, J. Bobes, A. Ahokas, I. Eggens, S. Liu, and H. Eriksson Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study The International Journal of Neuropsychopharmacology 13 2010 305 320
9. B. Bandelow, J. Zohar, E. Hollander, S. Kasper, and H.J. Möller World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision The World Journal of Biological Psychiatry 9 2008 248 312
10. L. Belanger, C.M. Morin, F. Langlois, and R. Ladouceur Insomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptoms Journal of Anxiety Disorders 18 2004 561 571
11. B.G. Bereza, M. Machado, and T.R. Einarson Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder Clinical Therapeutics 31 2009 1279 1308
12. S. Blank, E.J. Lenze, B.H. Mulsant, M.A. Dew, J.F. Karp, M.K. Shear, P.R. Houck, M.D. Miller, B.G. Pollock, B. Tracey, and C.F. Reynolds Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment Journal of Clinical Psychiatry 67 2006 468 472
13. V. Bollu, A.G. Bushmakin, J.C. Cappelleri, C.-C. Chen, D. Feltner, and H.-U. Wittchen Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms European Journal of Psychiatry 24 2010 18 27
14. D.J. Buysse, C.F. Reynolds III, T.H. Monk, S.R. Berman, and D.J. Kupfer The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research Psychiatry Research 28 1989 193 213
15. Canadian Psychiatric Association Clinical practice guidelines. Management of anxiety disorders Canadian Journal of Psychiatry 51 2006 9S 91S
16. J.S. Comer, C. Blanco, D.S. Hasin, S.M. Liu, B.F. Grant, J.B. Turner, and M. Olfson Health-related quality of life across the anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions (NESARC) Journal of Clinical Psychiatry 72 2011 43 50
17. J.R. Davidson, R.L. DuPont, D. Hedges, and J.T. Haskins Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder Journal of Clinical Psychiatry 60 1999 528 535
18. J.R. Davidson, D.E. Feltner, and A. Dugar Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs Primary Care Companion to the Journal of Clinical Psychiatry 2010 12
19. J. Endicott, J. Nee, W. Harrison, and R. Blumenthal Quality of life enjoyment and satisfaction questionnaire: a new measure Psychopharmacology Bulletin 29 1993 321 326
20. J. Endicott, J.M. Russell, J. Raskin, M.J. Detke, J. Erickson, S.G. Ball, M. Marciniak, and R.W. Swindle Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies Journal of Clinical Psychiatry 68 2007 518 524
21. D.L. Hoffman, E.M. Dukes, and H.U. Wittchen Human and economic burden of generalized anxiety disorder Depression and Anxiety 25 2008 72 90
22. M.A. Katzman, O. Brawman-Mintzer, E.B. Reyes, B. Olausson, S. Liu, and H. Eriksson Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial International Clinical Psychopharmacology 26 2011 11 24
23. R.C. Kessler, M. Gruber, J.M. Hettema, I. Hwang, N. Sampson, and K.A. Yonkers Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up Psychological Medicine 38 2008 365 374
24. A. Khan, M. Joyce, S. Atkinson, I. Eggens, I. Baldytcheva, and H. Eriksson A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder Journal of Clinical Psychopharmacology 31 2011 418 428
25. B.A. Marcks, R.B. Weisberg, M.O. Edelen, and M.B. Keller The relationship between sleep disturbance and the course of anxiety disorders in primary care patients Psychiatry Research 178 2010 487 492
26. J. Mendlewicz Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders The World Journal of Biological Psychiatry 10 2009 269 275
27. C. Merideth, A. Cutler, F. She, and H. Eriksson Efficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo-controlled and active-controlled study International Clinical Psychopharmacology 27 2012 40 54
28. I. Mezhebovsky, K. Magi, F. She, C. Datto, and H. Eriksson Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder International Journal of Geriatric Psychiatry 28 2013 615 625
29. S.A. Montgomery, B.K. Herman, E. Schweizer, and F.S. Mandel The efficacy of pregabalin and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia International Clinical Psychopharmacology 24 2009 214 222
30. National Institute for Health and Clinical Excellence, 2011. Generalised Anxiety Disorder and Panic Disorder (With or Without Agoraphobia) in Adults. Available at: http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf
31. M.H. Pollack, J. Endicott, M. Liebowitz, J. Russell, M. Detke, M. Spann, S. Ball, and R. Swindle Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment Journal of Psychiatric Research 42 2008 1042 1049
32. M.H. Pollack, S.G. Kornstein, M.E. Spann, P. Crits-Christoph, J. Raskin, and J.M. Russell Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint Journal of Psychiatric Research 42 2008 1176 1184
33. M.H. Pollack, R. Zaninelli, A. Goddard, J.P. McCafferty, K.M. Bellew, D.B. Burnham, and M.K. Iyengar Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial Journal of Clinical Psychiatry 62 2001 350 357
34. H.J. Ramsawh, M.B. Stein, S.L. Belik, F. Jacobi, and J. Sareen Relationship of anxiety disorders, sleep quality, and functional impairment in a community sample Journal of Psychiatric Research 43 2009 926 933
35. M. Rosenthal Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control Journal of Clinical Psychiatry 64 2003 1245 1249
36. A.J. Rush Handbook of Psychiatric Measures 2000 American Psychiatric Association Washington, DC
37. M. Rynn, J. Russell, J. Erickson, M.J. Detke, S. Ball, J. Dinkel, K. Rickels, and J. Raskin Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial Depression and Anxiety 25 2008 182 189
38. D.V. Sheehan The Anxiety Disease 1983 Charles Scribner and Sons New York, NY
39. D.V. Sheehan, K. Harnett-Sheehan, M.E. Spann, H.F. Thompson, and A. Prakash Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale International Clinical Psychopharmacology 26 2011 75 83
40. D.V. Sheehan, Y. Lecrubier, K.H. Sheehan, P. Amorim, J. Janavs, E. Weiller, T. Hergueta, R. Baker, and G.C. Dunbar The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 Journal of Clinical Psychiatry 59 Suppl. 20 1998 22 33
41. K.H. Sheehan, and D.V. Sheehan Assessing treatment effects in clinical trials with the discan metric of the Sheehan disability scale International Clinical Psychopharmacology 23 2008 70 83
42. S.M. Stahl, S. Ahmed, and V. Haudiquet Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER CNS Spectrums 12 2007 703 711
43. D.J. Stein, B. Bandelow, O.T. Dolberg, H.F. Andersen, and D.S. Baldwin Anxiety symptom severity and functional recovery or relapse Annals of Clinical Psychiatry 21 2009 81 88
44. H.U. Wittchen Generalized anxiety disorder: prevalence, burden, and cost to society Depression and Anxiety 16 2002 162 171
45. H.U. Wittchen, R.M. Carter, H. Pfister, S.A. Montgomery, and R.C. Kessler Disabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national survey International Clinical Psychopharmacology 15 2000 319 328